The Changing Pharma Commercial Model in 2010 and Beyond<\/strong> <\/p>\n
This article features a summary of the much anticipated NEW Kantar Health TRI*M annual survey results with physicians across the U.S. and Europe on their service expectations — plus how they rate 16 Pharma companies on reps, relationships and services. The survey looked not only at PCPs\/GPs but also — for the first time — at what oncologists expect from the industry.<\/p>\n
Expanded Summary Available<\/a>.<\/i> <\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Corporate Reputation in the New Media World<\/strong> <\/p>\n In an online webinar entitled ‘Reputation Strategies That Drive Results: Turning Your Good Name into Good Business’ Kantar Health explored the value of corporate reputation and corporate social responsibility from a traditional channel and digital media perspective and also from the view of understanding how this impacts the relationship between pharmaceutical and Key Opinion Leaders. This article summarizes the presentations made at that webinar. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n The European eMarketing Scene: Desperately Seeking Strategy<\/strong> <\/p>\n The pharmaceutical industry is struggling to develop an eMarketing strategy in Europe, which is comprised of many relatively small markets (the member countries of the EU) having significant cultural and language differences. <\/p>\n Expanded Summary Available<\/a>.<\/i> <\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Global Pharma Competitive Intelligence: A Necessity in Times of Economic Uncertainty<\/strong> <\/p>\n This year is proving to be a critical one for many industries, including the pharma-ceutical industry. Actionable, evidence-based and global pharmaceutical competitive intelligence (CI) and general business intelligence (BI) will play an important role in the drama about to unfold. <\/p>\n This article highlights several presentations made at the 2008 Pharmaceutical Competitive Intelligence Conference and discusses some common themes, including how environments for the pharmaceutical and device industries are changing dramatically with implications for CI going forward, the importance of keeping an eye on China, and whether CI is a strategic or tactical discipline. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n How to Sell a Drug Before it is Approved<\/strong> <\/p>\n Did you know that you can sell a drug before it is launched? Dr. Gene Emmer, President of Med Services Europe B.V., an Amsterdam-based consultancy focused on sales, marketing, and business development for the medical industry, advises his start-up, cash hungry, biotech companies to consider if a European “named patient program” might be an option. <\/p>\n Expanded Summary Available<\/a>.<\/i> <\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n The Indian Pharmaceutical Market<\/strong> <\/p>\n The Indian pharmaceutical market is the world’s fourth largest by volume (8% of global total) and thirteenth largest by value (less than 1% of global total). <\/p>\n Click Here for Full Text<\/a><\/b> – FREE! (pdf). <\/p>\n This article, written by a marketer with firsthand experience, provides an overview of the pharmaceutical markets and promotional practices in India. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Optimizing Market Access<\/strong> <\/p>\n A Guide to Effective Pricing, Reimbursement and Messaging Strategies<\/i><\/p>\n In today’s competitive market, pricing and reimbursement strategies are key to maximizing brand success and ROI. Because every country’shealthcare system is different-and every product situation is unique-every brand requires a specific access plan, tailored to each market. And you must support each plan with effective messaging that ensures strong product acceptance and uptake. Experts from TNS Healthcare spoke on this issue in a recent webinar and during an exclusive interview with Pharma Marketing News. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Owning the Prescription Pad: Driving Brand Decisions in a Multi-Influence World<\/strong> <\/p>\n The security of a controlled environment for pharma marketing communication is giving way to the complexities of a dynamic environment with more empowered players, including patients who have more influence than ever before over which products make it to market and which are prescribed. Brand managers need to observe, gauge and seek to influence those influencers. Therefore, we need a new model that helps us make sense of a complex world of communications. This article presents such a model developed by TNS Healthcare, A Kantar Health Company. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Pfizer France: Viva la SFE Difference!<\/strong> <\/p>\n Our European correspondent interviews Annick Pichavant Ruty, VP of Sales for Pfizer France. Surprisingly, according to Ms. Ruty, lack of sales rep time with physicians is not a problem for Pfizer France but she had other internal issues that needed to be addressed to build an effective sales force. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Pharmaceutical Market Access 2010<\/strong> <\/p>\n Future revenue growth in the US and EU will be limited as the EU wrestles with cost effectiveness and the US debates healthcare reforms. Meanwhile, pharma and biotech companies are looking to emerging market opportunities in Brazil, Russia, India, and China (i.e., BRIC) to drive future business. What does this all mean for patients, physicians, payers, and pharmaceutical\/biotech manufacturers? This article addresses that question. <\/p>\n Expanded Summary Available<\/a>.<\/i> <\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Pharmacy TeleStocking<\/strong> <\/p>\n Astute Development Group (ADG), a global provider of technology telemarketing and IT sales lead generation programs, manages pharmacy stocking from afar. <\/p>\n Click Here for Full Text<\/a><\/b> – FREE! (pdf). <\/p>\n This article reviews the results of the ‘Predicting the Future of the Drug Industry: 2010 & Beyond!’ survey and provides background on future trends. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n The State of CME in Europe: A Work in Progress<\/strong> <\/p>\n Continuing Medical Education (CME) in Europe has undergone some major shifts in recent years. These have varied across Europe: from national changes in which systems have moved from being voluntary to mandatory, to the establishment of more formal systems to guide physicians on how to keep up-to-date with latest clinical practice. <\/p>\n This article, written two European CME consultants, provides an overview of the state of CME in the UK, France, and other European countries.”> <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n Use of Social Media for Health Purposes in the EU<\/strong> <\/p>\n This article is a summary of the EPG Health Media (part of the IMR International Group) market research report ‘Social Media and Healthcare,’ which examines how European doctors, patients\/consumers and pharma engage (and seek to engage) with each other. <\/p>\n Expanded Summary Available<\/a>.<\/i><\/p>\n<\/p>\n Full Text Available – FREE<\/b><\/a>.<\/p>\n<\/p>\n Value-based Pricing<\/strong> <\/p>\n This article summarizes the second half of a presentation by Uday Bose, European marketing director for GlaxoSmithKline Oncology, in which he focuses on reform attempts within European countries and pharma’s reactions, the benefits and perils of risk-sharing agreements and how pharma might best meet the challenges of the marketplace now and into the future. <\/p>\n Expanded Summary Available<\/a>.<\/i> <\/p>\n<\/p>\n Order and pay for this reprint now using your credit card…<\/b> <\/p>\n
Download PDF file immediately after paying: <\/p>\n![\"Add](\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/02\/btn_cart_LG.gif\")
<\/a> <\/p>\n![\"View](\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2009\/01\/ej_view_cart.gif\")
<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n<\/a> ]]><\/p>\n<\/p>\n
Download PDF file immediately after paying: <\/p>\n<\/a> <\/p>\n